合并与不合并COVID-19的重症患者肾脏结局及肾小管损伤与功能轨迹
COVID-19宿主反应与结局研究前瞻性纳入华盛顿州ICU因下呼吸道感染症状入院的成人,入院时核酸检测确定COVID-19状态。经逆概率加权后分析330例患者,COVID-19与主要不良肾脏事件(MAKE,定义为血肌酐翻倍、肾脏替代治疗或死亡)风险升高70%相关(RR 1.70;95%CI 1.05-2.74),与肾脏替代治疗风险升高741%相关(RR 7.41;95%CI 1.69-32.41)。在181例有生物样本的患者中,COVID-19阴性组尿EGF、分泌清除率和eGFR随时间升高,而COVID-19阳性组保持不变;两组尿KIM-1均无显著变化。提示重症COVID-19患者尽管肾损伤程度相似,但近端肾小管功能障碍和eGFR下降病程更迁延。
要点
- 重症COVID-19患者MAKE(血肌酐翻倍、肾脏替代治疗或死亡)发生风险较无COVID-19者高70%(RR 1.70;95%CI 1.05-2.74)。
- 重症COVID-19患者肾脏替代治疗发生风险较无COVID-19者高741%(RR 7.41;95%CI 1.69-32.41)。
- COVID-19阴性组尿EGF、肾小管分泌清除率和eGFR随时间升高,COVID-19阳性组保持不变。
- 两组尿KIM-1浓度在研究期间均无显著变化。
- ICU入院时平均年龄55±16岁,45%需机械通气,平均血肌酐1.1 mg/dL。
适用人群与场景
- 前瞻性纳入因下呼吸道感染症状入住华盛顿州ICU的成人,入院时核酸检测确定COVID-19状态。
- 经逆概率加权后分析330例患者;其中181例有可用生物样本用于肾小管损伤与功能轨迹分析。
诊断标准与关键阈值
- 主要不良肾脏事件(MAKE)定义为血清肌酐翻倍、肾脏替代治疗或死亡。
- COVID-19状态由入院时核酸扩增检测确定。
研究设计与关键结果
- 研究类型为前瞻性队列研究(COVID-19宿主反应与结局研究),纳入ICU下呼吸道感染症状成人330例(逆概率加权分析)。
- ICU入院时平均年龄55±16岁,45%需机械通气,平均血清肌酐1.1 mg/dL。
- COVID-19与MAKE发生风险升高70%相关(RR 1.70;95%CI 1.05-2.74)。
- COVID-19与肾脏替代治疗发生风险升高741%相关(RR 7.41;95%CI 1.69-32.41)。
- 生物标志物队列中位随访测量3次;COVID-19阴性组尿EGF、分泌清除率和eGFR随时间升高,COVID-19阳性组保持不变。
- 两组尿KIM-1浓度在研究期间均无显著变化。
证据类型、等级与局限
- 证据类型:前瞻性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,重症COVID-19患者尽管肾损伤程度相似,但近端肾小管功能障碍和eGFR下降病程更迁延。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: COVID-19 may injure the kidney tubules via activation of inflammatory host responses and/or direct viral infiltration. Most studies of kidney injury in COVID-19 lacked contemporaneous controls or measured kidney biomarkers at a single time point.
OBJECTIVES: To better understand mechanisms of acute kidney injury in COVID-19, we compared kidney outcomes and trajectories of tubular injury, viability, and function in prospectively enrolled critically ill adults with and without COVID-19.
DESIGN, SETTING, AND PARTICIPANTS: The COVID-19 Host Response and Outcomes study prospectively enrolled patients admitted to ICUs in Washington State with symptoms of lower respiratory tract infection, determining COVID-19 status by nucleic acid amplification on arrival.
MAIN OUTCOMES AND MEASURES: We evaluated major adverse kidney events (MAKE) defined as a doubling of serum creatinine, kidney replacement therapy, or death, in 330 patients after inverse probability weighting. In the 181 patients with available biosamples, we determined trajectories of urine kidney injury molecule-1 (KIM-1) and epithelial growth factor (EGF), and urine:plasma ratios of endogenous markers of tubular secretory clearance.
RESULTS: At ICU admission, the mean age was 55 ± 16 years; 45% required mechanical ventilation; and the mean serum creatinine concentration was 1.1 mg/dL. COVID-19 was associated with a 70% greater occurrence of MAKE (relative risk 1.70; 95% CI, 1.05-2.74) and a 741% greater occurrence of KRT (relative risk 7.41; 95% CI, 1.69-32.41). The biomarker cohort had a median of three follow-up measurements. Urine EGF, secretory clearance ratios, and estimated glomerular filtration rate (eGFR) increased over time in the COVID-19 negative group but remained unchanged in the COVID-19 positive group. In contrast, urine KIM-1 concentrations did not significantly change over the course of the study in either group.
CONCLUSIONS: Among critically ill adults, COVID-19 is associated with a more protracted course of proximal tubular dysfunction and reduced eGFR despite similar degrees of kidney injury.
参考来源
- Granda ML, Tian F, Zelnick LR, et al. Kidney Outcomes and Trajectories of Tubular Injury and Function in Critically Ill Patients With and Without COVID-19. Crit Care Explor. 2024. PMID: 38922318. doi:10.1097/CCE.0000000000001109
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。